70 related articles for article (PubMed ID: 17692456)
41. MUC1-C drives DNA methylation in cancer.
Rajabi H; Tagde A; Kufe D
Aging (Albany NY); 2016 Dec; 8(12):3155-3156. PubMed ID: 28039441
[No Abstract] [Full Text] [Related]
42. NAV-003, a bispecific antibody targeting a unique mesothelin epitope and CD3ε with improved cytotoxicity against humoral immunosuppressed tumors.
Grasso L; Jiang Q; Hassan R; Nicolaides NC; Kline JB
Eur J Immunol; 2023 Aug; 53(8):e2250309. PubMed ID: 37146241
[TBL] [Abstract][Full Text] [Related]
43. Antitumor effect of a novel humanized MUC1 antibody-drug conjugate on triple-negative breast cancer.
Li L; Cao J; Chen C; Qin Y; He L; Gu H; Wu G
Heliyon; 2023 Apr; 9(4):e15164. PubMed ID: 37089317
[TBL] [Abstract][Full Text] [Related]
44. Therapeutic effect of a MUC1-specific monoclonal antibody-drug conjugates against pancreatic cancer model.
Wu G; Li L; Liu M; Chen C; Wang G; Jiang Z; Qin Y; He L; Li H; Cao J; Gu H
Cancer Cell Int; 2022 Dec; 22(1):417. PubMed ID: 36572921
[TBL] [Abstract][Full Text] [Related]
45. Potential of Anti-MUC1 Antibodies as a Targeted Therapy for Gastrointestinal Cancers.
Bose M; Mukherjee P
Vaccines (Basel); 2020 Nov; 8(4):. PubMed ID: 33167508
[TBL] [Abstract][Full Text] [Related]
46. An antibody-drug conjugate targeting a GSTA glycosite-signature epitope of MUC1 expressed by non-small cell lung cancer.
Pan D; Tang Y; Tong J; Xie C; Chen J; Feng C; Hwu P; Huang W; Zhou D
Cancer Med; 2020 Dec; 9(24):9529-9540. PubMed ID: 33084221
[TBL] [Abstract][Full Text] [Related]
47. TF-containing MUC1 glycopeptides fail to entice Galectin-1 recognition of tumor-associated Thomsen-Freidenreich (TF) antigen (CD176) in solution.
FitzGerald FG; Rodriguez Benavente MC; Garcia C; Rivero Y; Singh Y; Wang H; Fields GB; Cudic M
Glycoconj J; 2020 Dec; 37(6):657-666. PubMed ID: 33001366
[TBL] [Abstract][Full Text] [Related]
48. Preferential Localization of MUC1 Glycoprotein in Exosomes Secreted by Non-Small Cell Lung Carcinoma Cells.
Pan D; Chen J; Feng C; Wu W; Wang Y; Tong J; Zhou D
Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30646616
[TBL] [Abstract][Full Text] [Related]
49. Targeting the human MUC1-C oncoprotein with an antibody-drug conjugate.
Panchamoorthy G; Jin C; Raina D; Bharti A; Yamamoto M; Adeebge D; Zhao Q; Bronson R; Jiang S; Li L; Suzuki Y; Tagde A; Ghoroghchian PP; Wong KK; Kharbanda S; Kufe D
JCI Insight; 2018 Jun; 3(12):. PubMed ID: 29925694
[TBL] [Abstract][Full Text] [Related]
50. Endogenous antibody responses to mucin 1 in a large multiethnic cohort of patients with breast cancer and healthy controls: Role of immunoglobulin and Fcγ receptor genes.
Pandey JP; Namboodiri AM; Wolf B; Iwasaki M; Kasuga Y; Hamada GS; Tsugane S
Immunobiology; 2018 Feb; 223(2):178-182. PubMed ID: 29074302
[TBL] [Abstract][Full Text] [Related]
51. Molecular basis of antibody binding to mucin glycopeptides in lung cancer.
Qu J; Yu H; Li F; Zhang C; Trad A; Brooks C; Zhang B; Gong T; Guo Z; Li Y; Ragupathi G; Lou Y; Hwu P; Huang W; Zhou D
Int J Oncol; 2016 Feb; 48(2):587-94. PubMed ID: 26692014
[TBL] [Abstract][Full Text] [Related]
52. Genetic variants of IgG1 antibodies and FcγRIIIa receptors influence the magnitude of antibody-dependent cell-mediated cytotoxicity against prostate cancer cells.
Pandey JP; Namboodiri AM
Oncoimmunology; 2014 Jan; 3(1):e27317. PubMed ID: 24701371
[TBL] [Abstract][Full Text] [Related]
53. Natural and Induced Humoral Responses to MUC1.
Von Mensdorff-Pouilly S; Moreno M; Verheijen RH
Cancers (Basel); 2011 Jul; 3(3):3073-103. PubMed ID: 24212946
[TBL] [Abstract][Full Text] [Related]
54. Aberrantly glycosylated MUC1 is expressed on the surface of breast cancer cells and a target for antibody-dependent cell-mediated cytotoxicity.
Lavrsen K; Madsen CB; Rasch MG; Woetmann A; Ødum N; Mandel U; Clausen H; Pedersen AE; Wandall HH
Glycoconj J; 2013 Apr; 30(3):227-36. PubMed ID: 22878593
[TBL] [Abstract][Full Text] [Related]
55. Anti-MUC1 monoclonal antibody (C595) and docetaxel markedly reduce tumor burden and ascites, and prolong survival in an in vivo ovarian cancer model.
Wang L; Chen H; Pourgholami MH; Beretov J; Hao J; Chao H; Perkins AC; Kearsley JH; Li Y
PLoS One; 2011; 6(9):e24405. PubMed ID: 21931707
[TBL] [Abstract][Full Text] [Related]
56. Aptamer–biotin–streptavidin–C1q complexes can trigger the classical complement pathway to kill cancer cells.
Bruno JG
In Vitro Cell Dev Biol Anim; 2010 Feb; 46(2):107-13. PubMed ID: 19915929
[TBL] [Abstract][Full Text] [Related]
57. A genetic variant of immunoglobulin gamma2 is strongly associated with immunity to mucin 1 in patients with breast cancer.
Pandey JP; Nietert PJ; Klaamas K; Kurtenkov O
Cancer Immunol Immunother; 2009 Dec; 58(12):2025-9. PubMed ID: 19365631
[TBL] [Abstract][Full Text] [Related]
58. High level of MUC1 in serum of ovarian and breast cancer patients inhibits huHMFG-1 dependent cell-mediated cytotoxicity (ADCC).
Moreno M; Bontkes HJ; Scheper RJ; Kenemans P; Verheijen RH; von Mensdorff-Pouilly S
Cancer Lett; 2007 Nov; 257(1):47-55. PubMed ID: 17692456
[TBL] [Abstract][Full Text] [Related]
59. Toll-like receptor agonists and invariant natural killer T-cells enhance antibody-dependent cell-mediated cytotoxicity (ADCC).
Moreno M; Mol BM; von Mensdorff-Pouilly S; Verheijen RH; von Blomberg BM; van den Eertwegh AJ; Scheper RJ; Bontkes HJ
Cancer Lett; 2008 Dec; 272(1):70-6. PubMed ID: 18684557
[TBL] [Abstract][Full Text] [Related]
60. Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 Is independent of FcgammaRIIIa functional polymorphism.
Niwa R; Hatanaka S; Shoji-Hosaka E; Sakurada M; Kobayashi Y; Uehara A; Yokoi H; Nakamura K; Shitara K
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6248-55. PubMed ID: 15448014
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
